Oncolytics Biotech Investor Relations Material
Latest events
Q1 2025
Oncolytics Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Oncolytics Biotech Inc
Access all reports
Oncolytics Biotech Inc. (Oncolytics) is a development-stage biopharmaceutical company. The company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics' research and development activities are based on its proprietary lipid nanoparticle-laden virus, REOLYSIN. REOLYSIN is developed under Oncolytics' strategic alliance with BioCity Group Pty Ltd, an Australian government-backed translational research group focused on the improvement of cancer care via clinical and pharma applications for regenerative medicines. Oncolytics also has a license agreement with DaktariPharma UAB, a Lithuanian drug discovery company specializing in use of alternative medicine to treat cancer, for use of the oral formulation of cyclopamine in several European markets including Germany, France and Italy.
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
ONCY
Country
🇺🇸 United States